We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Sugar Could Replace Contrast Agents in Brain MRI Scans

By MedImaging International staff writers
Posted on 05 Jul 2017
Print article
Image: Visualization of brain cancer by conventional contrast agents (L) and using glucose MRI method (R) (Photo courtesy of DKFZ).
Image: Visualization of brain cancer by conventional contrast agents (L) and using glucose MRI method (R) (Photo courtesy of DKFZ).
A new study suggests that glucose metabolism activity identified using magnetic resonance imaging (MRI) could help identify solid tumors or very aggressively growing tumor areas.

Researchers at the German Cancer Research Center (DKFZ; Heidelberg, Germany), the Max-Planck-Institute for Biological Cybernetics (Tuebingen, Germany), and other institutions used an ultrahigh field 7 Tesla MRI scanner to detect intracerebral regions of increased glucose concentration. For the study, they examined nine patients with newly diagnosed glioblastoma and four healthy volunteers between October 2015 and July 2016.

T1ρ-weighted dynamic glucose-enhanced (DGE) MRI was performed with injection of 100 mL of 20% d-glucose via the cubital vein. Glucose enhancement, given by the relative signal intensity change, was then quantitatively investigated in brain gray matter versus white matter in the healthy volunteers, and in tumor tissue versus normal-appearing white matter of patients with glioblastoma. The median signal intensities of the assessed brain regions were then compared.

The results demonstrated that in healthy volunteers, the median signal intensity in basal ganglia gray matter was significantly increased compared with that in white matter tissue. But in the glioblastoma patients, the median signal intensity in the glucose-enhanced tumor region, as displayed on the T1ρ-weighted DGE images, was significantly higher than that in contralateral normal-appearing white matter, indicating the pathophysiologically increased glucose uptake that occurs in human brain cancer. The study was published on June 23, 2017, in Radiology.

“We do not know yet how the shares of measured glucose are distributed between vessels and extracellular spaces on the one hand, and the cell interior on the other,” said study co-author radiologist Heinz-Peter Schlemmer, MD, PhD, of the DKFZ division of radiology. “If we can confirm that substantial signal levels originate from glucose in the cell interior, this would be important additional information for tumor imaging and functional MRI. This could enhance therapy planning and monitoring.”

MRI contrast agents enhance signals in blood vessels and in spaces between cells, but do not reach the interior of the cell; by contrast, glucose is taken up and then broken down in the body cells, and tumor cells are particularly hungry for glucose in order to feed their high-energy needs. As glucose is found at much lower levels in the body, magnetization transfer effect is used to reinforce the glucose signal by transferring the signal from glucose protons to bodily water, which is measured in MRI. The amount of glucose needed corresponds to about five sugar cubes.

Related Links:
German Cancer Research Center
Max-Planck-Institute for Biological Cybernetics
New
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Digital X-Ray Detector Panel
Acuity G4
Radiology Software
DxWorks
Portable Color Doppler Ultrasound System
S5000

Print article

Channels

Radiography

view channel
Image: AI can identify “mammographically-visible” types of interval cancers earlier by flagging them at the time of screening (Photo courtesy of ScreenPoint Medical)

AI Improves Early Detection of Interval Breast Cancers

Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.